Genentech | tradingpattern.net

Stock Quotes

INDU	0.00		N/A
NASDAQ	2905.66		+45.98
S&P 500	1344.90		+19.36
AA	10.76		+0.34
AXP	52.25		+1.09
BA	76.34		+1.12
BAC	7.84		+0.39
CAT	113.94		+3.61
CSCO	20.09		+0.29
CVX	105.50		+1.81
DD	52.01		+0.61
DIS	40.00		+1.09
GE	19.02		+0.27
HD	45.17		+0.71
HPQ	29.07		+0.57
IBM	193.64		+2.11
INTC	26.74		+0.46
JNJ	65.64		+0.05
JPM	38.28		+0.73
KFT	38.88		+0.30
KO	68.08		+0.25
MCD	100.01		+1.39
MMM	87.73		+0.30
MRK	38.37		-0.07
MSFT	30.24		+0.29
PFE	21.20		+0.09
PG	62.77		-0.55
T	29.95		+0.16
TRV	60.12		+0.73
UTX	81.05		+1.03
VZ	37.84		+0.28
WMT	62.03		+0.09
XOM	84.92		+1.39
HL	5.40		+0.06
RDY	33.94		+0.29
FCX	46.48		+0.97
OXY	102.63		+4.15
GOOG	596.33		+11.22
LUV	10.04		+0.29
AFFX	5.14		0.00
AAPL	459.68		+4.56

1970-01-01 20:27

About tradingpattern.net

The movement of a security's price over a specific time period.

dedicated to value creation and applying the scientific method in finance

Search

network - market statistics - weekly update

High dividend yield stocks

Dogs of the Dow
Dogs of the S&P500
Dogs of the DAX
Dogs of the SMI

If you like the complete list, send us a mail to office@brokerbase.ch

network

3M Activision Blizzard Adobe Systems Affimetrix Airlines Akamai Tech Alcoa Altera Amazon.com American Express American Tower Amgen Amylin Pharma Analyst Rating AngloGold Apollo Group Apple Applied Materials AT&T Autodesk Automatic Data Processing Baidu Bank of America Baxter Bed Bath & Beyond Blackrock Boeing Broadcom C.H. Robinson CA Caterpillar Celgene Cephalon Charts Check Point Software Chevron Cintas Corporation Cisco Systems Citigroup Citrix Coca Cola Cognizant Comcast Costco Wholesale Cree Dell DENTSPLY DIRECTV Discount, Variety Stores DISH Disney Dow 30 Downgrade Dr. Reddy's Laboratories Du Pont eBay Electronic Arts EMC Corporation Expedia Express Scripts Extreme Networks Exxon Mobil Fastenal First Solar Fiserv Flextronics FLIR Ford Foster Wheeler FREDDIE MAC Freeport-McMoRan Garmin Genentech General Electric Genzyme Gilead Sciences Golden Star Resources Goldman Sachs Google Hansen Natural Hardware Healthcare Hecla Mining Henry Schein Hewlett Packard Hologic Home Depot Human Genome Science IBM Illumina Industry Infosys Initial Recommendation Intel InterActive Corp Intuit Intuitive Surgical Johnson & Johnson Joy Global JP Morgan Juniper Networks KKR KLA-Tencor Kraft Foods Lam Research Level 3 Liberty Global Liberty Media Life Technologies Linear Technology Lockheed Martin Logitech Marvell Technology MasterCard Maxim Integrated McDonalds Merck Merril Lynch Microchip Technology Microsoft Millicom Morgan Stanley Nasdaq 100 NetApp NETFLIX Network Network Appliance Newmont Mining News Corporation NII Holdings Noble NVIDIA O'Reilly Automotive Occidental Petroleum Oracle PACCAR Patterson Paychex Petrohawk PETROLEO BRASILEIRO Pfizer Procter & Gamble Qualcomm Quanta Renhe Commercial Holdings Research in Motion Riverbed Technology Ross Stores Royal Gold Ryanair S&P 500 salesforce.com SanDisk Seagate Sears Holdings Semiconductor - Integrated Circuits Services Sigma-Aldrich Software Southwest Airlines Staples Starbucks Steel & Iron Steel Dynamics Stericycle Symantec Synaptics Technology Teva Texas Instruments Ticker Travelers Uncategorized United Continental Holdings United Technologies Upgrade Urban Outfitters VeriSign Verizon Vertex Pharmaceuticals Visa Wal Mart Warner Chilcott Wells Fargo Wynn Resorts Xilinx XTO Yahoo Zoltek

network - archived market statistics

Blogroll

www.bearparc.info
- dynamic hedging, Portfolio optimization, quantitative research
- credit derivatives, CDS, CDO, CLN
- dynamic hedging
www.searchingalpha.com
www.seekingalpha.de
www.topinvestments.ch
www.tradingpattern.ch
www.tradingpattern.de

Recent Posts

Genentech

Genentech und Biogen reichen Patentklage gegen GSK ein

Thursday, March 25th, 2010

Genentech konkretisiert Jahresprognose

Tuesday, March 18th, 2008

Genentech Inc. hat am Freitag die Ergebnisprognosen für das laufende Fiskaljahr präzisiert. Demnach erwartet Genentech, für das laufende Geschäftsjahr einen Gewinn im Bereich von 3,35 bis 3,45 $ je Aktie, nach 3,30 bis 3,45 $ je Anteilsschein. Analysten gehen für das laufende Fiskaljahr von einem EPS von 3,43 Dollar sowie einem Umsatz von 13,04 Mrd. [...]

Genentech: Beraterausschuss gegen Zulassung von Avastin gegen Brustkrebs

Thursday, December 6th, 2007

Die amerikanische Genentech Inc., die US-Tochter des schweizerischen Pharmakonzern Roche Holding AG, hat einen Rückschlag erlitten. Ein Beraterausschuss der US-Arzneimittelbehörde FDA hat gegen die Zulassung des Krebsmittels Avastin zur Behandlung von Brustkrebs gestimmt.